Delta Project Management

delta-pm.com

Delta Project Management (DPM) is a San Francisco Bay Area-based provider of staff and consulting services for the biopharmaceutical, medical device, and pharmaceutical industries. Delta PM specializes in Capital Project Management, Commissioning and Qualification, Validation, Engineering Support, and Regulatory Compliance. DPM is also a recognized world-wide leader in the highly specialized area of diabetes marketing strategy.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

news image

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

Cell and Gene Therapy

VERGE GENOMICS HONORED BY GOLDMAN SACHS FOR ENTREPRENEURSHIP

Verge Genomics | October 17, 2022

news image

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence and human data to develop new drugs, announced today that Goldman Sachs is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California. Goldman Sachs selected Zhang from leaders and entrepreneurs across multiple industries. Verge deeply integrates n...

Read More

Industrial Impact

THE BRACKEN ORGANIZATIONS MERGE TO CREATE A GLOBAL PLATFORM TO SUPPORT LIFE SCIENCE AND DIGITAL HEALTH TEAMS

The Bracken Group | October 11, 2021

news image

Three unique companies with shared origins have now united to better serve their clients in the life sciences industry. The new entity will be known as The Bracken Group (Bracken) with three divisions of the original three companies. The combined companies' mission continues to be supporting the success of companies that improve health, using an integrated network of clients, consultants, and employees across the globe. I am delighted to bring the ...

Read More
news image

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More
news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More
news image

Cell and Gene Therapy

VERGE GENOMICS HONORED BY GOLDMAN SACHS FOR ENTREPRENEURSHIP

Verge Genomics | October 17, 2022

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence and human data to develop new drugs, announced today that Goldman Sachs is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California. Goldman Sachs selected Zhang from leaders and entrepreneurs across multiple industries. Verge deeply integrates n...

Read More
news image

Industrial Impact

THE BRACKEN ORGANIZATIONS MERGE TO CREATE A GLOBAL PLATFORM TO SUPPORT LIFE SCIENCE AND DIGITAL HEALTH TEAMS

The Bracken Group | October 11, 2021

Three unique companies with shared origins have now united to better serve their clients in the life sciences industry. The new entity will be known as The Bracken Group (Bracken) with three divisions of the original three companies. The combined companies' mission continues to be supporting the success of companies that improve health, using an integrated network of clients, consultants, and employees across the globe. I am delighted to bring the ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us